Could a diabetes shot curb heavy drinking? new trial aims to find out
NCT ID NCT07292519
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a weekly injection of tirzepatide (a diabetes drug) plus cognitive-behavioral therapy can help adults with alcohol use disorder and overweight or obesity reduce heavy drinking days. 46 participants will receive either the drug or a placebo shot for 8 weeks, along with counseling. The goal is to see if the combination cuts down on heavy drinking and improves health measures like weight and blood pressure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALCOHOL USE DISORDER (AUD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Drug Health Services, Royal Prince Alfred Hospital
Sydney, New South Wales, 2050, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new stomach and gut bypass surgery tackle obesity and diabetes?
- Can a Two-Drug combo tip the scales against obesity?
- Can Weight-Loss surgery change how medications work?
- Can a psychedelic compound help veterans and first responders with PTSD and alcohol use disorder?
- Coffee grounds probiotic could reshape gut health and fight inflammation
- Can shedding pounds reboot the Heart's exercise engine?